Clinical trial MONARCH3 I3Y-MC-JPBM
A randomized, double-blind, placebo-controlled, phase 3 study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Lilly |
| EudraCT Identifier | 2014-001502-18 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02246621 |
| Inclusion criteria | HR+/HER2- |
| Last update |